Header Logo

Connection

HELEN HESLOP to Cytomegalovirus

Back to Details
This is a "connection" page, showing publications HELEN HESLOP has written about Cytomegalovirus.
HELEN HESLOP
Connection Strength
1.735
Cytomegalovirus
  1. Pharmacotherapy versus T lymphocytes for CMV. Blood. 2013 May 02; 121(18):3544-5.
    View in: PubMed
    Score: 0.353
  2. Commentary on journal of immunotherapy paper by melenhorst et al. J Immunother. 2006 Jul-Aug; 29(4):365-6.
    View in: PubMed
    Score: 0.220
  3. Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
    View in: PubMed
    Score: 0.192
  4. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019 09 10; 3(17):2571-2580.
    View in: PubMed
    Score: 0.137
  5. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019 10; 187(2):206-218.
    View in: PubMed
    Score: 0.135
  6. CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63.
    View in: PubMed
    Score: 0.101
  7. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
    View in: PubMed
    Score: 0.088
  8. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11.
    View in: PubMed
    Score: 0.081
  9. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86.
    View in: PubMed
    Score: 0.077
  10. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.049
  11. Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy. 2018 09; 20(9):1182-1190.
    View in: PubMed
    Score: 0.032
  12. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.030
  13. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83.
    View in: PubMed
    Score: 0.024
  14. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.023
  15. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.022
  16. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
    View in: PubMed
    Score: 0.021
  17. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32.
    View in: PubMed
    Score: 0.021
  18. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.020
  19. Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990 Sep 01; 76(5):1046-53.
    View in: PubMed
    Score: 0.018
  20. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
    View in: PubMed
    Score: 0.018
  21. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
    View in: PubMed
    Score: 0.017
  22. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
    View in: PubMed
    Score: 0.016
  23. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.014
  24. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant. 2005 Nov; 11(11):912-20.
    View in: PubMed
    Score: 0.013
  25. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.